iCAD to Present at iAccess Alpha Buyside Best Ideas Fall Conference 2024

iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 By Investing.com

NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: NASDAQ:ICAD) (iCAD or the Company) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25. To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please visit the conference website at https://www.iaccessalpha.com/home. The iCAD presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/3064/51217. The iCAD presentation will also be available on the company's investor relations website under the Events & Earnings Calls tab. About iAccess Alpha iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two. About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Forward-Looking Statements Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI ®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 - icad (NASDAQ:ICAD)

NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. ICAD ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25. To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please visit the conference website at https://www.iaccessalpha.com/home. The iCAD presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/3064/51217. The iCAD presentation will also be available on the company's investor relations website under the Events & Earnings Calls tab. About iAccess Alpha iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two. About iCAD, Inc. iCAD, Inc. ICAD is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov. CONTACTS Media inquiries: [email protected] Investor Inquiries: John Nesbett/Rosalyn Christian IMS Investor Relations [email protected] Market News and Data brought to you by Benzinga APIs